You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
The new platform, called Fusion, is an addition to the Panther system and will run qPCR assays with three "mini panels" currently in the works.
The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.
The acquisition merges OvaGene's liquid biopsy technology and molecular diagnostics with Etta's point-of-care system.
The firm priced each share at $.47, and plans to use the funding for general corporate purposes and working capital.
The assay was demonstrated to be as effective as microscopy and a rapid immunoassay at detecting Plasmodium falciparum in a sample of febrile patients in Nigeria.
The scientists believe they have created a more accurate way to detect mutations that often lead to hereditary colorectal cancer.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.